Science Explorer Back to mapMap
Discussion
Nonprofit · Las Vegas · United States

Nevada Cancer Research Foundation

Research works
2
▼ 62% vs 2018-21
Citations
124
61.1 per fractional work
Top-10% rate
55.3%
all institutions 10.0%
Open access
71%
world 40%
International
36%
world 18%

Not ranked overall: Nevada Cancer Research Foundation is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Nevada Cancer Research Foundation work in?

In all years, 80% of research at Nevada Cancer Research Foundation is in Health Sciences, 15% in Life Sciences. Its largest fields are Medicine (80%), Biochemistry, Genetics and Molecular Biology (15%), Economics, Econometrics and Finance (5%). It does 1.3× the world's share of Health Sciences.

Life Sciences15%Health Sciences80%Social Sciences5%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 3 fields, with their numbers
    1. Medicine280.0%
    1. Biochemistry, Genetics and Molecular Biology015.0%
    1. Economics, Econometrics and Finance05.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Nevada Cancer Research Foundation?

The most cited paper from Nevada Cancer Research Foundation is "Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial" (Manish R. Patel, John Allan Ellerton, Jeffrey R. Infante et al., 2017), with 591 citations. Next come "Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma" (582) and "Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies" (252).

Most cited papers
#PaperReleasedCitations
1 Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial Manish R. Patel, John Allan Ellerton, Jeffrey R. Infante et al. · The Lancet Oncology Open access 5 Dec 2017 591
2 Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma W. C. Wood, Daniel R. Budman, Ann H. Korzun et al. · New England Journal of Medicine Open access 5 May 1994 582
3 Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies Gwénaëlle Gravis, Jean‐Marie Boher, Yu‐Hui Chen et al. · European Urology Open access 21 Feb 2018 252
4 Polypharmacy, Potentially Inappropriate Medications, and Drug-Drug Interactions in Vulnerable Older Adults With Advanced Cancer Initiating Cancer Treatment Erika E. Ramsdale, Mostafa Mohamed, Veronica Yu et al. · The Oncologist Open access Mar 2022 92
5 Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis Andrea Borghese Apolo, John Allan Ellerton, Jeffrey R. Infante et al. · Journal for ImmunoTherapy of Cancer Open access Oct 2020 84
All 15 most cited papers, with filters and sorting

Which research topics does Nevada Cancer Research Foundation publish most on?

By volume in 2022-now: Heart Failure Treatment and Management, Medication Adherence and Compliance, Pharmaceutical Practices and Patient Outcomes and Bladder and Urothelial Cancer Treatments.

  1. 1 Heart Failure Treatment and Management Cardiology and Cardiovascular Medicine 0 works
  2. 2 Medication Adherence and Compliance Family Practice 0 works
  3. 3 Pharmaceutical Practices and Patient Outcomes Geriatrics and Gerontology 0 works
  4. 4 Bladder and Urothelial Cancer Treatments Surgery 0 works
  5. 5 Healthcare Decision-Making and Restraints Clinical Psychology 0 works
  6. 6 Patient-Provider Communication in Healthcare General Health Professions 0 works
  7. 7 Palliative Care and End-of-Life Issues Public Health, Environmental and Occupational Health 0 works
  8. 8 Urinary and Genital Oncology Studies Surgery 0 works
  9. 9 Esophageal Cancer Research and Treatment Surgery 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available71.4%not open28.6%

World: 40% of research is openly available.

with international co-authors36.3%domestic only63.7%

World: 18% is written across borders.

How has Nevada Cancer Research Foundation's research output changed?

Output in 2022-2025 was 62% lower than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Nevada Cancer Research Foundation as a percentage of every work published that year, 0.0000011% in 2023.

still counting0.0000050%0.000010%0.000015%Nevada Cancer Research Foundation0.0000022% in 2025200020102020

Fractional works of Nevada Cancer Research Foundation over all fractional works that year. How the balance of science has shifted.

Other research institutions in Las Vegas

All research institutions in Las Vegas

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Nevada Cancer Research Foundation. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.